These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22414588)

  • 1. Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa.
    Pahuja M; Grobler A; Glesby MJ; Karim F; Parker G; Gumede S; Naidoo K
    Antivir Ther; 2012; 17(4):737-43. PubMed ID: 22414588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
    Moore RD; Wong WM; Keruly JC; McArthur JC
    AIDS; 2000 Feb; 14(3):273-8. PubMed ID: 10716503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.
    McGrath CJ; Njoroge J; John-Stewart GC; Kohler PK; Benki-Nugent SF; Thiga JW; Etyang A; Chung MH
    J Neurovirol; 2012 Jun; 18(3):200-4. PubMed ID: 22528481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic variation influences sensory neuropathy occurrence in Southern Africans treated with stavudine-containing antiretroviral therapy.
    Moketla MB; Wadley AL; Kamerman P; de Assis Rosa D
    PLoS One; 2018; 13(10):e0204111. PubMed ID: 30273369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study.
    Phan V; Thai S; Choun K; Lynen L; van Griensven J
    PLoS One; 2012; 7(1):e30647. PubMed ID: 22303447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects.
    Menezes CN; Maskew M; Sanne I; Crowther NJ; Raal FJ
    BMC Infect Dis; 2011 Sep; 11():244. PubMed ID: 21923929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
    van Griensven J; Zachariah R; Rasschaert F; Mugabo J; Atté EF; Reid T
    Trans R Soc Trop Med Hyg; 2010 Feb; 104(2):148-53. PubMed ID: 19732926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral neuropathy during stavudine-didanosine antiretroviral therapy.
    Reliquet V; Mussini JM; Chennebault JM; Lafeuillade A; Raffi F
    HIV Med; 2001 Apr; 2(2):92-6. PubMed ID: 11737385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usage of stavudine (D4T) - a retrospective analysis in a South London hospital.
    Lechelt M; McCormick S; de Ruiter A
    Int J STD AIDS; 2007 Mar; 18(3):215-7. PubMed ID: 17362559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
    Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A
    PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans.
    Wadley AL; Cherry CL; Price P; Kamerman PR
    J Pain Symptom Manage; 2011 Apr; 41(4):700-6. PubMed ID: 21145196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa.
    Maskew M; Westreich D; Fox MP; Maotoe T; Sanne IM
    J Int AIDS Soc; 2012 Mar; 15(1):13. PubMed ID: 22410312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.
    Kiwuwa-Muyingo S; Kikaire B; Mambule I; Musana H; Musoro G; Gilks CF; Levin JB; Walker AS
    AIDS; 2014 Nov; 28(17):2579-88. PubMed ID: 25574960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    ; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
    J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa.
    Stead D; Osler M; Boulle A; Rebe K; Meintjes G
    Antivir Ther; 2008; 13(7):937-43. PubMed ID: 19043928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
    Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
    Forna F; Liechty CA; Solberg P; Asiimwe F; Were W; Mermin J; Behumbiize P; Tong T; Brooks JT; Weidle PJ
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):456-62. PubMed ID: 17279048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
    Soorju V; Naidoo P
    Afr J Prim Health Care Fam Med; 2016 Oct; 8(1):e1-e6. PubMed ID: 28155312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.
    Dlamini J; Ledwaba L; Mokwena N; Mokhathi T; Orsega S; Tsoku M; Kowo H; Proschan M; Khabo P; Maja P; Hadigan C
    Antivir Ther; 2011; 16(4):605-9. PubMed ID: 21685549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study.
    Osler M; Stead D; Rebe K; Meintjes G; Boulle A
    HIV Med; 2010 Feb; 11(2):121-9. PubMed ID: 19702629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.